• General
  • Industry
  • Government & Politics
  • Other Language
  • Press Release
  • Home
  • Submit News
  • Contact Us
  • About Us
Pakistan Newswire
Menu
  • General
  • Industry
  • Government & Politics
  • Other Language
  • Press Release
 › Press Release › Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease  

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease  

Web Desk August 1, 2022     Comment Closed     Press Release

WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). The main objective of the Phase 1/2 is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

TED is a debilitating vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. With no approved therapies for TED patients in China, treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) intended for the treatment of TED.

“We are proud that the IND application for ZB001 was approved by the NMPA about two months following its submission, highlighting our team’s unique ability to efficiently execute on our development programs,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “We are excited to work with leading clinical experts in China to accelerate the development of ZB001 to address the significant unmet clinical need in thyroid eye disease.”

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics, Inc. (Viridian) in October 2020. After submitting an IND for VRDN-001 to the U.S. Food and Drug Administration in October 2021, Viridian initiated a Phase 1/2 clinical trial in December 2021 to evaluate proof of concept in TED patients in North America and released encouraging interim healthy volunteer data suggesting robust activity with excellent safety and tolerability of the candidate product.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Press Release
AfricaMENAPakistanSouth Africa

 Previous Post

Import bill declines to $5b in July: Miftah Ismail

― July 30, 2022

Next Post 

AOP Health Starts Research for Leukemia Treatment

― August 1, 2022

Related Articles

Web Desk ― February 1, 2023 | Comment Closed

FOLK HERO™ expands globally with push into Europe and the Middle East

New York, NY, Feb. 01, 2023 (GLOBE NEWSWIRE) — FOLK HERO™, [INVNT GROUP]’s brand strategy firm, is expanding its global operations into Europe and the Middle East, growing its storytelling reach across the region. FOLK HERO is a modern brand studio, brand consulting agency, and leading expert in global brand storytelling. The firm has led […]

Web Desk ― February 1, 2023 | Comment Closed

SAUDI ARABIA WINS HOSTING RIGHTS OF THE AFC ASIAN CUP™ 2027

Web Desk ― February 1, 2023 | Comment Closed

HYCU® Introduces World’s First Data Protection Development Platform for SaaS

Web Desk ― February 1, 2023 | Comment Closed

Boyden Appoints Distinguished Talent Solutions Leader Chad Hesters President & CEO

Web Desk ― February 1, 2023 | Comment Closed

SMPO Releases CP01 Disposable Pod Kit With Multiple Flavors And Large Capacity

Web Desk ― January 31, 2023 | Comment Closed

‫ایس اینڈ پی ڈاؤ جونز سسٹین ایبلٹی انڈیکس (ڈی جے ایس آئی) 2022 رینکنگ میں ویدانتا ایلومینیم دوسرے نمبر پر ہے

Web Desk ― January 31, 2023 | Comment Closed

‫ٹی اے کیو اے مشرق وسطی، شمالی افریقہ، وسطی ایشیا اور مشرقی یورپ تک توسیع کے لئے المنصوری پیٹرولیم سروسز کے 100 فیصد حصول کے لین دین بند کردی

Web Desk ― January 31, 2023 | Comment Closed

Vedanta Aluminium ranks 2nd in S&P Dow Jones Sustainability Index (DJSI) 2022 rankings

Search

Follow Us

Recent Posts

  • There is no room for forced conversion or marriage in Islam: Abdul Shakoor January 31, 2023
  • UNEP reiterates support to ‘Living Indus Initiative’ in Pakistan January 31, 2023
  • Pakistan, Russia agree to boost cooperation in diverse sectors January 31, 2023
  • Death toll in Peshawar blast rises to 100 January 31, 2023
  • PM terms terrorism as foremost national security challenge January 31, 2023
  • KP observes one-day mourning as death toll of Peshawar terror attack soars to 93 January 31, 2023
  • Development of Balochistan Govt’s top priority: PM January 31, 2023
  • CJCSC, IMCTC Secretary-General discuss counter-terrorism cooperation January 31, 2023
  • Pakistan-China border crossing at Khunjerab Pass re-opened for transportation January 30, 2023
  • PM expresses grief over death of children in Kohat boat mishap January 30, 2023
  • PM appeals to people for blood donations for injured in Peshawar terrorist attack January 30, 2023
  • AJK President urges Kashmiri, Pakistani diaspora to highlight plight of Kashmiris January 30, 2023

Advertisement

Calendar

February 2023
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728  
« Jan    


The strategy of the team behind “Pakistan news Wire.Net” is clear and it is to publish only authentic news as that is what the true journalism demands from any media outlet, and the “Pakistan News Wire. Net”, discourages the practice of opting for illegal approaches in order to get the ratings by any means. The more media outlets opt [...]

Archives

Search

Pages

  • Home
  • Submit News
  • Contact Us
  • About Us

Social Links

Copyright © 2020 - Pakistan News Wire. All Rights Reserved.